Feliciano Barrón1Roberto Sánchez1
Marisol Arroyo-Hernández1Carolina Blanco2
Zyanya L. Zatarain-Barrón1
Rodrigo Catalán1Maritza Ramos-Ramírez1
Andrés F. Cardona3,4,5Diana Flores-Estrada1
Oscar Arrieta1*- 1Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, Mexico
- 2Cancer Center, ABC Medical Center, México City, Mexico
- 3Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia
- 4Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia
- 5Clinical Research and Biology Systems Department, Universidad el Bosque, Bogotá, Colombia
By Barrón F, Sánchez R, Arroyo-Hernández M, Blanco C, Zatarain-Barrón ZL, Catalán R, Ramos-Ramírez M, Cardona AF, Flores-Estrada D and Arrieta O (2020) Front. Oncol. 10:570233. doi: 10.3389/fonc.2020.570233
In the published article, the “No. (Events)” values for the “Wood-smoke exposure” row and Pneumonitis rows in Table 3 were transcribed incorrectly during table formatting. The Cox analysis for wood-smoke exposure and both pneumonitis categories (any grade and ≥2) were performed with the correct underlying data; only the “No. (Events)” figures in that row are misprinted.
Table 3. Factors associated with overall survival.
The corrected table appears below.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: checkpoint immune therapy, pneumonitis, radiotherapy, NSCLC, lung cancer, immune related adverse effects
Citation: Barrón F, Sánchez R, Arroyo-Hernández M, Blanco C, Zatarain-Barrón ZL, Catalán R, Ramos-Ramírez M, Cardona AF, Flores-Estrada D and Arrieta O (2026) Correction: Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy. Front. Oncol. 16:1783059. doi: 10.3389/fonc.2026.1783059
Received: 07 January 2026; Accepted: 19 January 2026;
Published: 06 February 2026.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2026 Barrón, Sánchez, Arroyo-Hernández, Blanco, Zatarain-Barrón, Catalán, Ramos-Ramírez, Cardona, Flores-Estrada and Arrieta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Oscar Arrieta, b2dhckB1bmFtLm14